Issue
Copyright (c) 2025 E. Prabhakar Reddy, Hemanth Raj Thangappazham, Nabnita Patnaik, Pragathi Duggina, Kuladeep L Kumar, Saurabh Varshney, Ashoo Grover, Pratima Gupta, Kumar Guru Mishra, Seshadri Reddy Varikasuvu
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.Impact of metformin therapy on serum visfatin levels in polycystic ovary syndrome: a systematic review and randomized permuted meta-analysis
Corresponding Author(s) : Seshadri Reddy Varikasuvu
Cellular and Molecular Biology,
Vol. 71 No. 2: Issue 2
Abstract
Visfatin, an, is associated with reproductive and metabolic disorders like polycystic ovary syndrome (PCOS). Although visfatin levels are known to be elevated in PCOS, the effect of metformin treatment on these levels remains unclear. This meta-analysis aimed to assess changes in circulating visfatin levels before and after metformin intervention in PCOS patients. Relevant studies were identified through comprehensive searches, and a random-effects meta-analysis was conducted to calculate standardized mean differences (SMDs) with 95% confidence intervals (CIs). Sensitivity analysis and randomized permuted meta-analyses (with 1,000, 10,000, and 100,000 iterations) were performed to validate the findings. The analysis included four studies and showed a significant reduction in visfatin levels following metformin treatment (SMD: -0.45, 95% CI: -0.76 to -0.14, p = 0.0043). These results highlight metformin's impact on visfatin levels in PCOS, though larger trials are needed to further explore visfatin's role as a therapeutic target in PCOS.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
